指南与共识

ESMO全球联盟研究:抗癌药物可及性、自付费用与可获得性2023年更新

ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update.
指南 / 共识 · Ann Oncol · 2025-01-16

该研究通过在线调查评估170个国家中基本抗癌药物及八种高发癌症用药的目录可及性、自付费用和实际可获得性,最终由126个国家的317名报告者和231名同行评审者提供数据。结果显示多数高收入国家患者无需显著自付即可获得抗癌药物,包括ESMO-MCBS高分新疗法;而中低收入国家中,WHO基本药物目录所列40%的传统化疗药仅能以全自费方式获得。

要点

  • 多数高收入国家患者无需显著自付即可获得抗癌药物,包括ESMO-MCBS高分新疗法。
  • 中低收入国家中,WHO基本药物目录所列40%的传统化疗药仅以全自费方式提供。
  • 该数据集为抗癌药物可及性不平等提供全球参考,以推动公共卫生政策。

核心结论

  • 该数据集提供了新的全球参考,以加强对抗癌药物可及性与可获得性不平等的问责,并识别挑战与不足以推动公共卫生政策。

研究设计与样本

  • 基于既往验证方法的在线调查研究,评估基本仿制抗癌药及八种高发癌症用药的目录可及性、自付费用和实际可获得性。
  • 邀请170个国家的853名现场报告者参与,最终由126个国家的317名报告者和231名同行评审者提供数据。
  • 数据在ESMO网站上汇总并同行评审,据此做出最终调整。

主要发现

  • 多数高收入国家患者无需显著自付即可获得抗癌药物,包括ESMO-MCBS高分新疗法。
  • 中低收入国家中,WHO基本药物目录所列40%的传统化疗药仅以全自费方式提供。

关键数值与推荐

  • 评估药物包括WHO第22版基本药物目录所列基本仿制抗癌药及八种高发癌症用药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The availability and affordability of safe, effective cancer therapies are core requirements for effective cancer control. Global disparities exist in access, however, yielding unequal cancer outcomes. The goal of this study was to provide updated data regarding the formulary availability, out-of-pocket costs, and accessibility of cancer medicines in countries across the full spectrum of economic development areas. METHODS: This study was conducted through an online survey based on a previously validated methodology. It evaluated the formulary availability, out of pocket costs, and actual accessibility of essential generic cancer medication commonly used for a wide range of cancers, including those on the 22nd WHO Model List of Essential Medicines (EML), and cancer medications used in eight high-incidence cancers. A total of 853 field reporters from 170 countries were invited to participate. The collected data were collated and peer-reviewed on the ESMO website, with final adjustments made accordingly. RESULTS: Data were collected by 317 reporters and 231 peer reviewers across 126 countries. The study revealed that patients in most high-income countries can access cancer medications without significant out-of-pocket expenditure, including novel treatments with high ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scores. Conversely, in lower-middle and low-income countries, 40% of traditional chemotherapy agents deemed essential in the WHO EML are only available at full cost to patients. CONCLUSIONS: This dataset provides a new and updated 'Global Reference' to enhance accountability for inequalities in access and availability of cancer medicines and to identify challenges and shortcomings to drive public health policies and positively impact national cancer control planning.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Cherny NI, Trapani D, Galotti M, et al. ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update. Ann Oncol. 2025. PMID: 39818519. doi:10.1016/j.annonc.2024.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。